Cue Biopharma Files 8-K: Material Agreement, Other Events
Ticker: CUE · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1645460
Sentiment: neutral
Topics: material-agreement, corporate-events, filing
TL;DR
Cue Biopharma filed an 8-K on 12/19/25 for a material agreement and other events.
AI Summary
On December 19, 2025, Cue Biopharma, Inc. filed an 8-K report. The filing indicates a material definitive agreement was entered into, and also reports other events and financial statements/exhibits. The company was formerly known as Imagen Biopharma, Inc. until June 17, 2015.
Why It Matters
This 8-K filing signals significant corporate activity, potentially including new partnerships or strategic deals, which could impact the company's future development and stock performance.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to significant stock price movements, but the specific nature of the agreement is not detailed here, requiring further investigation.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Imagen Biopharma, Inc. (company) — Former company name
- December 19, 2025 (date) — Date of earliest event reported
- 001-38327 (other) — Commission File Number
- 47-3324577 (other) — IRS Employer Identification No.
- 40 Guest Street Boston , Massachusetts 02135 (address) — Principal executive offices
- (617) 949-2680 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Cue Biopharma, Inc. on December 19, 2025?
The filing states that a material definitive agreement was entered into, but the specific details of this agreement are not provided in the provided text.
What other events are reported in the 8-K filing dated December 19, 2025?
The filing indicates 'Other Events' are reported, but the specifics are not detailed in the provided text.
When did Cue Biopharma, Inc. change its name from Imagen Biopharma, Inc.?
The company formerly known as Imagen Biopharma, Inc. changed its name on June 17, 2015.
What is the principal executive office address for Cue Biopharma, Inc.?
The principal executive offices are located at 40 Guest Street, Boston, Massachusetts 02135.
What is the Commission File Number for Cue Biopharma, Inc.?
The Commission File Number for Cue Biopharma, Inc. is 001-38327.
Filing Stats: 2,385 words · 10 min read · ~8 pages · Grade level 13.5 · Accepted 2025-12-19 16:22:55
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share CUE Nasdaq Capital Market
- $0.28 — Warrant at a combined offering price of $0.28 (allocated as $0.279 per Firm Share and
- $0.279 — d offering price of $0.28 (allocated as $0.279 per Firm Share and $0.001 per Firm Comm
- $0.278 — offering price of $0.279 (allocated as $0.278 per Pre-Funded Warrant and $0.001 per F
- $0.2632 — riting Agreement at a combined price of $0.2632 and (ii) each Pre-Funded Warrant and ac
- $0.2622 — riting Agreement at a combined price of $0.2622. Under the terms of the Underwriting Ag
- $8.9 m — from the offering will be approximately $8.9 million, or approximately $10.3 million i
- $10.3 million — ximately $8.9 million, or approximately $10.3 million if the Underwriters exercise in full th
- $0.30 — nt will have an exercise price equal to $0.30. Each Common Stock Warrant will be exer
- $5.0 million — nd marketable securities, including the $5.0 million in upfront payments the Company has rec
Filing Documents
- d213128d8k.htm (8-K) — 43KB
- d213128dex11.htm (EX-1.1) — 198KB
- d213128dex41.htm (EX-4.1) — 57KB
- d213128dex42.htm (EX-4.2) — 79KB
- d213128dex51.htm (EX-5.1) — 13KB
- d213128dex991.htm (EX-99.1) — 12KB
- g213128g1219122215628.jpg (GRAPHIC) — 3KB
- g213128g1219145145008.jpg (GRAPHIC) — 2KB
- g213128g1219145747522.jpg (GRAPHIC) — 5KB
- 0001193125-25-326925.txt ( ) — 637KB
- cue-20251219.xsd (EX-101.SCH) — 3KB
- cue-20251219_lab.xml (EX-101.LAB) — 17KB
- cue-20251219_pre.xml (EX-101.PRE) — 11KB
- d213128d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated December 19, 2025, by and between Cue Biopharma, Inc. and H.C. Wainwright & Co., LLC, as representative of the underwriters named therein 4.1 Form of Pre-Funded Warrant 4.2 Form of Common Stock Warrant 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) 99.1 Press Release dated December 19, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL) Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the expected closing of the public offering, the Underwriters' option to purchase additional securities and the Company's cash runway. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "anticipate," "believe," "continue," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "seek," "strategy," "future," "vision," "should," "target," "will," "would," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the satisfaction of customary closing conditions related to the offering; the Com
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2025 CUE BIOPHARMA, INC. By: /s/ Usman Azam Name: Usman Azam Title: President and Chief Executive Officer